Stock·NASDAQ·Healthcare
Tilray Brands Inc. (TLRY)
- Market cap
- $448.54M
- Dividend yield
- 0.00%
- Street target
- $5.50median of 10 analysts
- 52-week range
- $3.03 $16.20
The short version
Where TLRY stands today, in four lines, and what CleaRank Financial AI makes of it.
TLRY at a glance
Tilray Brands Inc. (TLRY): Sell, 38/100 on CleaRank's AI score.
- Trend Down: the price is below both its 50- and 200-day moving averages ($4.15 and $5.80).
- Earnings TLRY beat estimates in 1 of its last 3 quarters, yet fell the next day after every one of them.
- Insiders Insiders sold $233K and bought $193K over the last 18 months.
Figures as of October 16, 2026.
CleaRank Financial AI
CleaRank rates Tilray Brands Inc. (TLRY) Sell, with a model score of 38/100.
Revenue growth lifts the score most: revenue grew 22.70%, 14.6 percentage points faster than the sector median. The trend holds it back most: the price is 47.65% below its 200-day average and 26.93% below its 50-day average, and the 50-day average is 28.36% below the 200-day. The 50-day average stands at $4.15 and the 200-day at $5.80. Over the past year the price fell 80.29%.
Only on CleaRank
Figures we compute ourselves from TLRY's own price, earnings and insider-filing history. Tap one to see it in context.
Price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
0/4Price above its 50-day average ›
The price of $3.04 is 26.9% below the 50-day simple moving average of $4.15.Price above its 200-day average ›
The price is 47.7% below the 200-day simple moving average of $5.80.50-day average above the 200-day ›
The 50-day average ($4.15) is 28.4% below the 200-day average ($5.80), the arrangement of a falling longer-term trend.In the upper half of its 52-week range ›
The price sits at 0% of its 52-week range, between $3.03 and $16.20.
TLRY share price
Pick a period: each tab shows how far TLRY has moved over it, to the last close.
Today's trading
Where TLRY sits inside today's range and its 52-week range.
Fundamentals
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
1/3P/S below the sector median ›
The price-to-sales ratio of 0.49 is 85.5% below the sector median of 3.4.Profitable over the last 12 months ›
Net income over the last 12 months was $-164.2M on revenue of $963.1M, a net margin of -17.1%.Beat estimates in most recent reports ›
TLRY beat the EPS estimate in 1 of its last 3 reports.
Key statistics
The headline figures for TLRY.
As of October 16, 2026, TLRY trades at $3.04, with a market value of $448.54M and no P/E ratio (its trailing earnings are negative).
What the numbers say
CleaRank Financial AI's reading of TLRY's valuation, growth and risks.
Tilray Brands Inc. (TLRY) has no meaningful P/E, because the company lost money over the last 12 months. Looking at sales instead, its P/S of 0.49 sits 85.6% below the sector median P/S of 3.4. The stock has a market value of $448.5M, and its trailing earnings are -$1.38 a share.
Tilray Brands Inc. is not yet profitable. Its net margin stands at -17.05% and its operating margin at -6.23%. Revenue grew 22.70% in the latest year, which is 14.6 percentage points faster than the sector median of 8.1%. Return on equity is -9.38%, below the sector median of 7.3%. Debt-to-equity of 0.23 completes the picture.
The October 8, 2026 report was a beat: -$0.02 a share came in against an estimate of -$0.14, a gap of 85.71% above expectations. Even so, the share price fell 1.39% in the following session.
TLRY beat the EPS estimate in 1 of its last 3 reports, but the stock fell in the first session after that beat. Analysts expect EPS of $0.06012 for this fiscal year and $0.1776 for the next, so the current-year figure implies a decline of 45.3%.
Day-to-day swings are the main thing to plan around, since TLRY has moved 2.71% on an average session. The downtrend adds further risk for as long as the price remains below both moving averages. The price is 81.27% below its 52-week high of $16.20.
TLRY against the Healthcare sector
How TLRY compares with the median Healthcare stock CleaRank tracks.
Price to sales vs sector: On price-to-sales, the yardstick used here in place of P/E, TLRY trades at 0.4926x, far below the sector average of 3.40x.
Return vs XLV: Since May 6, 2025, TLRY has lost 27.7% against a gain of 31.4% for XLV.
Performance against XLV
TLRY and the Healthcare sector fund over the same days.
Revenue and earnings
How much TLRY sells, and how much of it becomes profit.
Revenue growth: Revenue grew 11.5% in FY2026 to $915M, from $821M a year earlier.
Profit margin: The net margin was -11.5% in FY2026, up from -265.6% the year before.
Profitable: TLRY lost $105M in FY2026.
Earnings reality check
Did TLRY beat what analysts expected, and how did the stock react?
Earnings record: TLRY beat the analyst estimate in 1 of the last 3 quarters.
Market reaction: The stock fell in the first session after 1 of those 1 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Oct 8, 2026after close | -$0.14 | -$0.02 | +85.71% | -1.39% | -10.58% |
| Jul 28, 2026after close | $0.21 | $0.05 | -76.19% | -0.99% | +15.14% |
| Apr 7, 2025after close | -$0.04 | -$0.10 | -150.00% | -20.69% | -15.52% |
As of October 16, 2026, TLRY has beaten the analyst EPS estimate in 1 of its last 3 reported quarters and fell in the first trading session after it; its latest report, on October 8, 2026, came in 85.71% above the estimate and the stock moved -1.39% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
AI analysis and technicals
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
0/3RSI not overbought or oversold ›
The 14-day RSI is 24.7, in oversold territory.RSI above 50 ›
An RSI of 24.7 is below the 50 midpoint, so sellers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is negative, so the 12-day average is below the 26-day average.
CleaRank AI analysis of TLRY
The score, the reasoning behind it, and what could move the price next.
Tilray Brands Inc. (TLRY) is in a downtrend: both moving averages sit above the price. At $3.04, the stock is 26.93% below its 50-day average of $4.15 and 47.65% below its 200-day average of $5.80. The price is 0.17% above the 52-week low of $3.03, which places it at 0% of its 52-week range. The 50-day average is 28.36% below the 200-day, a gap that backs up the weak trend rather than cutting against it.
On momentum, the 14-day RSI reads 24.7, in oversold territory, with the MACD line negative. Every period on the chart shows a loss, with the price down 29.42% over the past three months, 55.76% over the past six months and 80.29% over the past year.
Earnings beat ›
The October 8, 2026 report beat the EPS estimate by 85.71%, and the share price fell 1.39% in the first session after it.
Source: Earnings report, October 8, 2026
Rating reaffirmed ›
Canaccord Genuity kept its Hold rating on October 9, 2026.
Source: Analyst action, Canaccord Genuity, October 9, 2026
- Two levels matter most: the 20-day EMA at $3.61, which sits above the price, and the 52-week low at $3.03, which sits below it.
- With the 14-day RSI at 24.7, TLRY is in the oversold zone and the MACD line is negative. Readings above 70 or below 30 point to stretched momentum.
- The share price fell 1.39% in the first session after the October 8, 2026 report. TLRY has beaten estimates in 1 of its last 3 reports.
TLRY remains in a downtrend while it trades below both its 50-day average of $4.15 and its 200-day average of $5.80. A close back above the 50-day average would mark the first sign of repair. Overhead, the 20-day EMA at $3.61 is the first level the price would meet on a rise.
The next level below the price is the 52-week low at $3.03. The RSI is in oversold territory, and a move back above the oversold line would be the first sign that selling pressure is easing.
Technical indicators
Momentum and trend for TLRY, from its daily closes.
As of October 16, 2026, with TLRY at $3.04, its 14-day RSI is 24.7 (oversold territory), its 50-day simple moving average is $4.15 and its 200-day is $5.80.
Calculated by CleaRank on daily closes as of October 16, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
What TLRY moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 16, 2026, TLRY's 1-year correlation of daily returns is +0.28 with S&P 500 (SPY), +0.26 with Nasdaq 100 (QQQ), +0.24 with Bitcoin (BTC) and +0.05 with gold (XAU).
What Wall Street expects
The analysts' target range and how their ratings split.
Analysts checks
1/3Most analysts rate it a buy ›
3 of 10 analysts rate it a buy or strong buy, 7 a hold and 0 a sell.Median target above the price ›
The median 12-month target of $5.50 is 81.2% above the price.More buy ratings than three months ago ›
3 of 10 rate it a buy now, against 3 of 10 three months ago.
TLRY Wall Street View
12-month price targets
The price, $3.04, sits below every analyst's target.
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 9, 2026 | Canaccord Genuity | Maintains | Hold |
| Jul 14, 2026 | TD Cowen | Maintains | Buy |
As of October 16, 2026, 10 Wall Street analysts cover TLRY: 3 rate it a buy or strong buy, 7 a hold and 0 a sell or strong sell. Their 12-month price targets range from $4.00 to $17.00, with a median of $5.50, 81.2% above the price of $3.04.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
A trade plan, if you want one
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
TLRY trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Short entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from TLRY's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much TLRY tends to move, against the market and on its own.
The long record
TLRY's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
0/4Average daily move under 2% ›
The price has moved 2.71% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 99.8%, from October 2018 to October 2026; the price is still 99.8% below that peak.Most 1-year holds ended higher ›
21% of 1-year holding periods in the last 8 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in July 2018 is now worth $143.37, against $31,195 in the S&P 500 (SPY).
TLRY Drawdowns & Recovery
As of October 16, 2026, TLRY's worst peak-to-trough fall over the last 8 years with dividends reinvested was -99.8% (October 2018 to October 2026); it is still 99.8% below that peak, and 21% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into TLRY in July 2018 is worth now, against the same amount in the S&P 500.
Against the market: TLRY trailed the S&P 500 over this period: $143.37 against $31,195.
A $10,000 investment in TLRY in July 2018 would be worth about $143 today with dividends reinvested, compared with about $31,195 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to TLRY, and which have not.
Strongest month, August: an average of +28.55%, up in 6 of 9 years.
Weakest month, April: an average of -20.05%, up in 0 of 8 years.
This month, October: has averaged -0.61%, up in 3 of 8 years. Past seasonality does not repeat on schedule.
Over the last 9 years, TLRY's strongest calendar month has been August (average +28.55%, up in 6 of 9 years) and its weakest April (average -20.05%, up in 0 of 8 years).
Average return for each calendar month over the last 9 years, from weekly closing prices with dividends included.
Long-term scenarios
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in TLRY, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in TLRY today could grow to about $3,016 by 2036 in the base case, with a 90th-percentile outcome near $22,881 and a 10th-percentile outcome around $398. Projections are statistical simulations, not guarantees.
TLRY Stock Price Prediction: 2030
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $1.88 for TLRY by 2030 in the base case, from $3.04 today (0.6x over 4 years). The 10th-percentile path ends near $0.5216. These are outcomes of a Monte Carlo simulation run on TLRY's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $1.42 | $2.69 | $5.11 | |
| 2028 | $0.9649 | $2.39 | $5.91 | |
| 2029 | $0.6982 | $2.12 | $6.43 | |
| 2030 | $0.5216 | $1.88 | $6.77 | |
| 2031 | $0.3977 | $1.67 | $6.98 |
Method: a lognormal simulation of TLRY's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles.
Insider trading
What the people running the company have bought and sold.
TLRY insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Insider buying: Insiders bought $193K on the open market and sold $233K.
As of October 16, 2026, TLRY insiders reported 1 open-market sale worth $233K and 6 open-market purchases worth $193K over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Aug 26, 2026 | Denise M Faltischek
Officer
|
Grant | 178.2K | - |
| Aug 26, 2026 | Mitchell S Gendel
General Counsel
|
Grant | 160.3K | - |
| Aug 26, 2026 | Carl A. Merton
Chief Financial Officer
|
Grant | 168.5K | - |
| Aug 26, 2026 | Irwin David Simon
Chief Executive Officer
|
Grant | 1.2M | - |
| Aug 6, 2026 | Mitchell S Gendel
Officer
|
Buy | 2.5K | $11.1K |
| Aug 4, 2026 | Carl A. Merton
Chief Financial Officer
|
Buy | 10.0K | $46.2K |
| Aug 3, 2026 | Denise M Faltischek
Officer
|
Buy | 2.5K | $12.0K |
| Jul 30, 2026 | Denise M Faltischek
Officer
|
Grant | 119.8K | - |
| Jul 30, 2026 | Mitchell S Gendel
Officer
|
Grant | 111.8K | - |
| Jul 30, 2026 | Carl A. Merton
Chief Financial Officer
|
Grant | 77.1K | - |
| Jul 30, 2026 | Irwin David Simon
Chief Executive Officer
|
Grant | 546.1K | - |
| Jul 29, 2026 | David F Clanachan
Director
|
Grant | 43.1K | - |
| Jul 29, 2026 | Steven Michael Cohen
Director
|
Grant | 43.1K | - |
| Jul 29, 2026 | Johann Michael Herhalt
Director
|
Grant | 43.1K | - |
| Jul 29, 2026 | David G. Hopkinson
Director
|
Grant | 43.1K | - |
| Jul 29, 2026 | Thomas Patrick Looney
Director
|
Grant | 43.1K | - |
| Jul 29, 2026 | Renah Persofsky
Director
|
Grant | 43.1K | - |
| Apr 21, 2026 | David G. Hopkinson
Director
|
Sell | 33.6K | $232.9K |
| Jan 7, 2026 | Steven Michael Cohen
Director
|
Option | 12.4K | $111.8K |
| Jul 31, 2025 | Denise M Faltischek
Officer
|
Option | 93.9K | $54.5K |
| Jul 31, 2025 | Mitchell S Gendel
General Counsel
|
Buy | 6.0K | $3.5K |
| Jul 31, 2025 | Mitchell S Gendel
General Counsel
|
Option | 93.9K | $54.5K |
| Jul 31, 2025 | Carl A. Merton
Chief Financial Officer
|
Option | 93.9K | $54.5K |
| Jul 31, 2025 | Irwin David Simon
Chief Executive Officer
|
Option | 706.2K | $409.6K |
| Jul 30, 2025 | David F Clanachan
Director
|
Option | 124.4K | $75.9K |
| Jul 30, 2025 | Denise M Faltischek
Officer
|
Grant | 261.2K | - |
| Jul 30, 2025 | Mitchell S Gendel
Officer
|
Option | 243.8K | $148.7K |
| Jul 30, 2025 | Johann Michael Herhalt
Director
|
Grant | 124.4K | - |
| Jul 30, 2025 | David G. Hopkinson
Director
|
Option | 124.4K | $75.9K |
| Jul 30, 2025 | Thomas Patrick Looney
Director
|
Grant | 124.4K | - |
| Jul 30, 2025 | Carl A. Merton
Chief Financial Officer
|
Option | 166.6K | $101.6K |
| Jul 30, 2025 | Carl A. Merton
Chief Financial Officer
|
Buy | 33.5K | $19.9K |
| Jul 30, 2025 | Renah Persofsky
Director
|
Option | 124.4K | $75.9K |
| Jul 30, 2025 | Irwin David Simon
Chief Executive Officer
|
Grant | 1.2M | - |
| Jul 30, 2025 | Irwin David Simon
Chief Executive Officer
|
Buy | 165.0K | $100.1K |
| Jun 2, 2025 | Denise M Faltischek
Officer
|
Option | 249.4K | $102.2K |
| Jun 2, 2025 | Mitchell S Gendel
Officer
|
Option | 231.2K | $94.8K |
| Jun 2, 2025 | Carl A. Merton
Chief Financial Officer
|
Option | 174.5K | $71.5K |
| Jun 2, 2025 | Irwin David Simon
Chief Executive Officer
|
Option | 1.2M | $483.0K |
Source: TwelveData, from reported insider filings
Questions people ask
Answered from the figures on this page, as of October 16, 2026.